Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An ambispective cohort study to determine efficacy and safety of pembrolizumab combination in real world setting in patients with early triple negative breast cancer

Next Previous
Trial Profile

An ambispective cohort study to determine efficacy and safety of pembrolizumab combination in real world setting in patients with early triple negative breast cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 09 Feb 2023 New trial record
  • 10 Dec 2022 Results presented at the 45th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top